Advertisement
Skip to Content

Regenerx Biopharmaceuticals Inc RGRX Stock Quote

| Rating as of

PINX: RGRX

Last close prices updated as of Feb 08, 2023, 9:30 AM EST | USD
  • Last Close 0.1439
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style
  • Day Range 0.14  –  0.14
  • Year Range 0.10  –  0.30
  • Market Cap 19.5228 Mil
  • Volume / Avg 8,401.0 /  35,068.3
  • Price / Sales 269.13
  • Price / Book
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis RGRX

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics RGRX

Company Profile RGRX

Business Description

Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.

Contact
15245 Shady Grove Road, Suite 470
Rockville, MD, 20850
Industry Biotechnology
Employees 3

FAQs for Regenerx Biopharmaceuticals Inc Stock

No. RGRX does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

RGRX’s market cap is 19.52 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

RGRX’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare RGRX’s historical performance against its industry peers and the overall market.